Physician profile
Ella Remenson
NPI 1316056237
$1,305.71
in general payments reported to CMS, 2019-2025
23 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $23.43 · 2021: $101 · 2022: $76.99 · 2023: $465 · 2024: $177 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $158.22 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Idorsia Pharmaceuticals US INC | $145.25 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $133.91 | 2021-2023 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $116.83 | 2025 | Caplyta |
| Novo Nordisk INC | $92.20 | 2019-2023 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $81.35 | 2019-2025 | Veozah |
| Exact Sciences Corporation | $75.22 | 2024-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $72.72 | 2019-2024 | |
| Pfizer INC. | $64.68 | 2023-2024 | |
| Abbvie INC. | $56.54 | 2022-2025 | |
| Acella Pharmaceuticals, LLC | $43.72 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $39.57 | 2019 | |
| Lucid Diagnostics INC. | $34.16 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $26.35 | 2024 | Rexulti |
| Abbott Laboratories | $24.38 | 2023 | Freestyle Libre 3 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $24.17 | 2019 | |
| Merz North America, INC. | $22.00 | 2019 | |
| Hologic Sales and Service, LLC | $21.40 | 2023 | Thinprep 2000 Processor, Aptima |
| Amarin Pharma, INC. | $15.87 | 2019 | |
| Bausch Health US, LLC | $15.22 | 2019 | |
| Amgen INC. | $15.00 | 2023 | Otezla, Repatha |
| Azurity Pharmaceuticals, INC. | $14.20 | 2023 | Adthyza |
| Virtus Pharmaceuticals LLC | $12.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ella Remenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.